RUBIN EYAL (Sr. VP & CFO) received a stock award from PROTALIX BIOTHERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/28/2022ACC: 0001104659-22-028159
Officer· Sr. VP & CFO
Since Sep 2019
+121.95K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
121.95K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+121.95K
Price / share
—
Trade value
—
% of position
49.5%
2/25/2022
246.15K→368.10K
Total
Net shares
+121.95K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 2/25/2022 | A · Award | +121.95K | — | — | 49.5% | 246.15K | 368.10K |
| Total | +121.95K | $0.00 | ||||||
Derivative Transactions0
No derivative transactions reported